AR049698A1 - Formulaciones solidas de tetrodotoxina que pueden ingerirse por via oral - Google Patents

Formulaciones solidas de tetrodotoxina que pueden ingerirse por via oral

Info

Publication number
AR049698A1
AR049698A1 ARP050102577A ARP050102577A AR049698A1 AR 049698 A1 AR049698 A1 AR 049698A1 AR P050102577 A ARP050102577 A AR P050102577A AR P050102577 A ARP050102577 A AR P050102577A AR 049698 A1 AR049698 A1 AR 049698A1
Authority
AR
Argentina
Prior art keywords
tetrodotoxina
inged
oral route
solid formulations
solid
Prior art date
Application number
ARP050102577A
Other languages
English (en)
Inventor
Weiyang Lin
Claude Cardinal
Frank Haykong Shum
Original Assignee
Wex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35481453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049698(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wex Pharmaceuticals Inc filed Critical Wex Pharmaceuticals Inc
Publication of AR049698A1 publication Critical patent/AR049698A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente se refiere a formulaciones orales aparentemente solidas o completamente solidas (o disenadas para ser ingeridas por vía oral) de tetrodotoxina y/o análogos o derivados de tetrodotoxina.
ARP050102577A 2004-06-22 2005-06-22 Formulaciones solidas de tetrodotoxina que pueden ingerirse por via oral AR049698A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/872,528 US20050282836A1 (en) 2004-06-22 2004-06-22 Solid orally ingestible formulations of tetrodotoxin

Publications (1)

Publication Number Publication Date
AR049698A1 true AR049698A1 (es) 2006-08-30

Family

ID=35481453

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102577A AR049698A1 (es) 2004-06-22 2005-06-22 Formulaciones solidas de tetrodotoxina que pueden ingerirse por via oral

Country Status (8)

Country Link
US (1) US20050282836A1 (es)
EP (1) EP1765353A1 (es)
CN (1) CN1972689A (es)
AR (1) AR049698A1 (es)
CA (1) CA2570709A1 (es)
PE (1) PE20060460A1 (es)
TW (1) TW200600098A (es)
WO (1) WO2005123088A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2808282C (en) * 2010-08-25 2018-06-05 Qihui Jessica Zhu Improved enteric active substance delivery
CN106063780B (zh) * 2016-06-28 2019-08-02 自然资源部第三海洋研究所 一种替曲朵辛速释微丸制剂、制备方法及其应用
CN105919979B (zh) * 2016-06-28 2019-07-02 国家海洋局第三海洋研究所 一种替曲朵辛肠溶缓释微丸、制备方法及其应用
CN107349204A (zh) * 2017-07-11 2017-11-17 东新皓特（北京）生化科技有限公司 河豚毒素在制备治疗带状疱疹病症药物组合物中的应用、药物组合物及外用药
CN107349205A (zh) * 2017-07-11 2017-11-17 东新皓特（北京）生化科技有限公司 河豚毒素在制备治疗犬瘟热的药物组合物中应用、药物组合物、制备方法及药物制剂
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特（北京）生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药
CN107308166A (zh) * 2017-07-11 2017-11-03 东新皓特（北京）生化科技有限公司 河豚毒素在制备治疗前列腺病症药物组合物中的应用、药物组合物及制备方法
CN107349314A (zh) * 2017-07-11 2017-11-17 东新皓特（北京）生化科技有限公司 河豚毒素在制备治疗中老年人性功能减退病症药物组合物中的应用、及药物组合物
CN107349206A (zh) * 2017-07-11 2017-11-17 东新皓特（北京）生化科技有限公司 河豚毒素在制备治疗新型毒品不良症状及复吸的药物组合物中的应用
CN112704665A (zh) * 2021-01-08 2021-04-27 江苏宏锦天药业有限公司 替曲朵辛口服制剂、替曲朵辛冻干片及其应用
CN115475151A (zh) * 2022-08-14 2022-12-16 中国人民解放军海军军医大学 河豚毒素缓释微球及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510221A (ja) * 1994-03-17 1997-10-14 ナンニン メープル リーフ ファーマスーティカル カンパニー リミテッド 薬物依存からの離脱のためのアミノ水素化キナゾリン化合物およびそれらの誘導体の用途
AU6883798A (en) * 1997-04-02 1998-10-22 Regents Of The University Of California, The Method of anesthesia
CN1085532C (zh) * 1998-06-09 2002-05-29 河北省水产研究所 一种戒除药物依赖性的药剂
CN1284536C (zh) * 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1382443A (zh) * 2001-04-25 2002-12-04 威克斯医疗仪器有限公司 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用
CN100360133C (zh) * 2002-05-23 2008-01-09 潘心富 用于戒毒、镇痛的河豚毒素呼吸道给药制剂

Also Published As

Publication number Publication date
CA2570709A1 (en) 2005-12-29
US20050282836A1 (en) 2005-12-22
WO2005123088A1 (en) 2005-12-29
CN1972689A (zh) 2007-05-30
EP1765353A1 (en) 2007-03-28
PE20060460A1 (es) 2006-06-02
TW200600098A (en) 2006-01-01

Similar Documents

Publication Publication Date Title
AR049698A1 (es) Formulaciones solidas de tetrodotoxina que pueden ingerirse por via oral
GT200900292A (es) "inhibidores de cinasa p70 s6"
GT200900010A (es) Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
CR11789A (es) Formulaciones orales de analogos citidina y metodos para el uso de los mismos
GT200400239A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
HN2008000874A (es) Metodo para obtener una composicion farmaceutica dispersable oralmente para la administracion mucoso oral o sublingual de agometalina
BRPI1008213A2 (pt) composições efervecentes e/ou solúveis por via oral contendo pelo menos um sal de s-adenosil metionina(same)
FR2881652B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesuage
FR2892937B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesusage
GT200600194A (es) Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada
UY29266A1 (es) Compuestos de piridazinona
CR9746A (es) Bazedoxifene acetate formulations
GT200900027A (es) Compuestos organicos
BRPI0509184A (pt) composições farmacêuticas
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
NO20051467D0 (no) Orale doseringsformer som innbefatter gemcitabinderivater
ECSP066291A (es) Sistemas emulsionantes que contienen derivados de azetidina
AR059423A1 (es) Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables
HN2006029142A (es) Proceso
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
CR10422A (es) Formulaciones de dosificacion solida
DK1837019T3 (da) Orale dispergerbare farmaceutiske sammensætninger
UY27618A1 (es) Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico

Legal Events

Date Code Title Description
FB Suspension of granting procedure